IDYA
Price
$22.41
Change
-$1.22 (-5.16%)
Updated
Aug 7 closing price
Capitalization
1.96B
95 days until earnings call
REGN
Price
$559.80
Change
+$4.67 (+0.84%)
Updated
Aug 7, 04:59 PM (EDT)
Capitalization
58.84B
84 days until earnings call
Interact to see
Advertisement

IDYA vs REGN

Header iconIDYA vs REGN Comparison
Open Charts IDYA vs REGNBanner chart's image
IDEAYA Biosciences
Price$22.41
Change-$1.22 (-5.16%)
Volume$673.15K
Capitalization1.96B
Regeneron Pharmaceuticals
Price$559.80
Change+$4.67 (+0.84%)
Volume$5.2K
Capitalization58.84B
IDYA vs REGN Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. REGN commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and REGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (IDYA: $22.41 vs. REGN: $559.80)
Brand notoriety: IDYA: Not notable vs. REGN: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 63% vs. REGN: 78%
Market capitalization -- IDYA: $1.96B vs. REGN: $58.84B
IDYA [@Biotechnology] is valued at $1.96B. REGN’s [@Biotechnology] market capitalization is $58.84B. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileREGN’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • REGN’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than IDYA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while REGN’s TA Score has 5 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 5 bearish.
  • REGN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, REGN is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а -7.97% price change this week, while REGN (@Biotechnology) price change was +2.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

REGN is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($58.8B) has a higher market cap than IDYA($1.96B). IDYA YTD gains are higher at: -12.802 vs. REGN (-21.853). REGN has higher annual earnings (EBITDA): 5.42B vs. IDYA (-356.46M). REGN has more cash in the bank: 7.47B vs. IDYA (693M). IDYA has less debt than REGN: IDYA (26M) vs REGN (2.71B). REGN has higher revenues than IDYA: REGN (14.2B) vs IDYA (7M).
IDYAREGNIDYA / REGN
Capitalization1.96B58.8B3%
EBITDA-356.46M5.42B-7%
Gain YTD-12.802-21.85359%
P/E RatioN/A13.99-
Revenue7M14.2B0%
Total Cash693M7.47B9%
Total Debt26M2.71B1%
FUNDAMENTALS RATINGS
IDYA vs REGN: Fundamental Ratings
IDYA
REGN
OUTLOOK RATING
1..100
7166
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
4
Undervalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
9654
PRICE GROWTH RATING
1..100
4862
P/E GROWTH RATING
1..100
10095
SEASONALITY SCORE
1..100
5048

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for IDYA (62) in the null industry. This means that REGN’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's Profit vs Risk Rating (78) in the null industry is in the same range as REGN (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REGN’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for IDYA (96) in the null industry. This means that REGN’s stock grew somewhat faster than IDYA’s over the last 12 months.

IDYA's Price Growth Rating (48) in the null industry is in the same range as REGN (62) in the Biotechnology industry. This means that IDYA’s stock grew similarly to REGN’s over the last 12 months.

REGN's P/E Growth Rating (95) in the Biotechnology industry is in the same range as IDYA (100) in the null industry. This means that REGN’s stock grew similarly to IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAREGN
RSI
ODDS (%)
Bearish Trend 1 day ago
64%
Bearish Trend 2 days ago
44%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 2 days ago
49%
MACD
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 2 days ago
64%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 15 days ago
77%
Bullish Trend 4 days ago
61%
Declines
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 2 days ago
55%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 7 days ago
56%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
65%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MGMT41.110.52
+1.29%
Ballast Small/Mid Cap ETF
SKOR48.830.02
+0.05%
FlexShares Credit-Scored US Corp Bd ETF
LIAU227.34N/A
N/A
LifeX 2060 Infl-Prt Longevity Inc ETF
TCAF36.36-0.01
-0.03%
T. Rowe Price Capital Apprec Eq ETF
ZSL23.35-0.14
-0.60%
ProShares UltraShort Silver

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with ROIV. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-2.59%
ROIV - REGN
42%
Loosely correlated
+0.17%
IDYA - REGN
40%
Loosely correlated
-2.03%
KRYS - REGN
40%
Loosely correlated
-0.98%
ACLX - REGN
39%
Loosely correlated
-1.90%
TECH - REGN
38%
Loosely correlated
-8.73%
More